Chacko David M.
Known title: Chief Financial OfficerCIK: 0001871801
Associated companies
Transaction History
| ERAS | ▼ Sell | Other | 17,793 | $21K | 12/15/2025 | View on chart |
| ERAS | ▼ Sell | Other | 12,324 | $19K | 12/13/2024 | View on chart |
| ERAS | ▼ Sell | Other | 3,137 | $5K | 6/14/2024 | View on chart |
| ERAS | ▼ Sell | Other | 7,478 | $12K | 12/15/2023 | View on chart |
| ERAS | ▼ Sell | Other | 1,748 | $7K | 2/1/2023 | View on chart |
| ERAS | ▼ Sell | Other | 2 | $8 | 2/1/2023 | View on chart |
| ERAS | ▼ Sell | Other | 1,562 | $18K | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Erasca Faces Verastem Competition Amid Clinical Updates
Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.
Erasca Faces Verastem Competition Amid Clinical Updates. Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.